Eli Lilly dominates the U.S. obesity/diabetes market at 60.9%, recently securing UK approval for oral Foundayo. However, the company faces a revived Michigan insulin pricing probe and battles 14,000+ lawsuits against fake Retatrutide, a Phase III drug with only 50% approval odds. Watch for the Michigan AG's next steps and Retatrutide's 2025 outlook.